Contineum Therapeutics, Inc. (CTNM)
NASDAQ: CTNM · Real-Time Price · USD
14.82
+0.72 (5.11%)
Mar 4, 2026, 2:36 PM EST - Market open
Contineum Therapeutics Stock Forecast
Stock Price Forecast
The 5 analysts with 12-month price forecasts for Contineum Therapeutics stock have an average target of 18.6, with a low estimate of 14 and a high estimate of 23. The average target predicts an increase of 25.51% from the current stock price of 14.82.
Analyst Consensus: Buy
* Price targets were last updated on Jan 8, 2026.
Analyst Ratings
The average analyst rating for Contineum Therapeutics stock from 5 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Sep '25 | Oct '25 | Nov '25 | Dec '25 | Jan '26 | Feb '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Buy | 4 | 4 | 4 | 4 | 3 | 3 |
| Hold | 0 | 0 | 0 | 0 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 5 | 5 | 5 | 5 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Morgan Stanley | Morgan Stanley | Buy → Hold Downgrades $23 → $14 | Buy → Hold | Downgrades | $23 → $14 | -5.53% | Jan 8, 2026 |
| Baird | Baird | Buy Maintains $16 → $14 | Buy | Maintains | $16 → $14 | -5.53% | Nov 24, 2025 |
| RBC Capital | RBC Capital | Buy Maintains $25 → $22 | Buy | Maintains | $25 → $22 | +48.45% | Nov 21, 2025 |
| Leerink Partners | Leerink Partners | Buy Initiates $20 | Buy | Initiates | $20 | +34.95% | Sep 25, 2025 |
| Morgan Stanley | Morgan Stanley | Buy Maintains $20 → $21 | Buy | Maintains | $20 → $21 | +41.70% | Aug 18, 2025 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-2.11
from -2.18
EPS Next Year
-2.24
from -2.11
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | n/a | n/a | ||||
| Avg | n/a | n/a | ||||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | -1.25 | -2.00 | ||||
| Avg | -2.11 | -2.24 | ||||
| Low | -2.23 | -2.69 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.